Prothena Corporation plc (Nasdaq: PRTA) is a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of novel investigational therapies with the potential to change the course of devastating rare peripheral amyloid and neurodegenerative diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged.